−1.59USD
−97.34 MUSD
2.81 MUSD
58.69 M
About Fulcrum Therapeutics, Inc.
Sector
CEO
Alexander C. Sapir
Headquarters
Cambridge
Website
Employees (FY)
76
Founded
2015
FIGI
BBG00DDY1RK9
Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.
FULC fades after a big move for a SHORT tradeFULC a biotechnology firm with a mixed earnings report early in the month just
printed a big move and then stalled at the NY lunch - hour and faded. Will the fade
continue or will there be an upward continuation? The 15 -minute chart seems to suggest
a downtrend:
1, The volume profile shows he
FULC Biotech Fib Level BouncdFULC on the 15 minute chart had a good response to favorable earnings and then retraced.
It is now bounding off the Fib 0.5 level and also confluent with the POC line of the volume
profile and the mean of the anchored VWAP. Buying volume appropriately overtook selling
volume on the reversal
Stock Idea: $FULC (31 Jan 2023)$FULC
- Consolidating in tight range while surfing 10 DMA
- Tightening up after strong run up
- Strong momentum runner: +150% in 1 month
$FULC is gonna fall todayPupm&Dump trading strategy idea.
$FULC is rising too much today.
The demand for shares of the company looks lower than the supply.
This and other conditions can cause a fall in the share price today.
So I opened a short position from $20,49;
stop-loss — $21,32;
take-profit — $18,82/MOC
Do not v
Fulcrum Therapeutics Announces Positive Interim Results from PhaFULC: Fulcrum Therapeutics, Inc.
2021-08-10 07:00:00
Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease
FULC SendFULC news catalyst popped the stock into the previous gap and right back to testing this clear resistance level that was previous support. After plotting the fib retracement is looks like the 50 Fib line is an area that might need to set up as the higher support level if there's any hope of FULC su
BioPharma with potential and gaps above I like the chart here but it will depend on a catalyst to drive it higher. A nice place to start accumulating shares.
FULC, Technical reversal play .First of All , shout out to Horizontal Price Levels Trading (on tradingview), I originally read their publication on FULC which was what spurred my original interest.
Secondly,
Bio-tech is NOT my strong point , as I do not have a medical background and reading the news reports these kinds of stoc
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of FULC is 7.28 USD — it has decreased by 2.15% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Fulcrum Therapeutics, Inc. stocks are traded under the ticker FULC.
Fulcrum Therapeutics, Inc. is going to release the next earnings report on May 14, 2024. Keep track of upcoming events with our Earnings Calendar.
FULC stock is 3.66% volatile and has beta coefficient of 2.14. Check out the list of the most volatile stocks — is Fulcrum Therapeutics, Inc. there?
FULC earnings for the last quarter are −0.39 USD per share, whereas the estimation was −0.44 USD resulting in a 11.50% surprise. The estimated earnings for the next quarter are −0.43 USD per share. See more details about Fulcrum Therapeutics, Inc. earnings.
Fulcrum Therapeutics, Inc. revenue for the last quarter amounts to 759.00 K USD despite the estimated figure of 1.05 M USD. In the next quarter revenue is expected to reach 552.72 K USD.
Yes, you can track Fulcrum Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
FULC stock has fallen by 2.02% compared to the previous week, the month change is a 24.72% fall, over the last year Fulcrum Therapeutics, Inc. has showed a 175.76% increase.
FULC net income for the last quarter is −24.76 M USD, while the quarter before that showed −24.02 M USD of net income which accounts for −3.08% change. Track more Fulcrum Therapeutics, Inc. financial stats to get the full picture.
Today Fulcrum Therapeutics, Inc. has the market capitalization of 460.80 M, it has decreased by 2.16% over the last week.
No, FULC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, FULC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Fulcrum Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 24, 2024, the company has 76.00 employees. See our rating of the largest employees — is Fulcrum Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Fulcrum Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Fulcrum Therapeutics, Inc. stock shows the neutral signal. See more of Fulcrum Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Fulcrum Therapeutics, Inc. future price: according to them, FULC price has a max estimate of 19.00 USD and a min estimate of 5.00 USD. Read a more detailed Fulcrum Therapeutics, Inc. forecast: see what analysts think of Fulcrum Therapeutics, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Fulcrum Therapeutics, Inc. EBITDA is −108.49 M USD, and current EBITDA margin is −3.87 K%. See more stats in Fulcrum Therapeutics, Inc. financial statements.